Irritable Bowel Syndrome Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - 4D pharma, Cosmo Pharmaceuticals, RedHill Biopharma Limited

(Las Vegas, Nevada, United States) "Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast- 2032" by DelveInsight provides a comprehensive analysis of Irritable Bowel Syndrome , including a detailed examination of its historical and projected Irritable Bowel Syndrome epidemiology. Additionally, the report offers insights into the Irritable Bowel Syndrome market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, aiming to enhance the understanding of this condition.

Download Sample Report to know more
https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Irritable Bowel Syndrome Overview
Irritable bowel syndrome is a chronic, often debilitating, and highly prevalent disorder of gut-brain interaction (previously called functional gastrointestinal disorders). It is the most commonly diagnosed lower gastrointestinal tract condition and the most common reason for referral to gastroenterology clinics.
Irritable bowel syndrome is a group of symptoms that occur together, not a disease but a functional disorder, which means that the bowel does not work normally. The symptoms of IBS may include abdominal pain, distention, bloating, indigestion, and various symptoms of defecation. Its hallmark is abdominal pain or discomfort associated with a change in the consistency and/or frequency of bowel movements. Each patient's symptoms are unique. While IBS may occur as an occasional nuisance for some people, others may experience intense pain that compromises their quality of life.

Click here to learn more about the Irritable Bowel Syndrome Market Landscape @https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlight from Irritable Bowel Syndrome Market Report:
Irritable bowel syndrome is believed to be a multifactorial disease involving motility dysfunction, visceral hypersensitivity, psychiatric comorbidity, neuroendocrine dysfunction, genetics and epigenetics, diet, and immune activation. Despite the high prevalence of irritable bowel syndrome, its diagnosis and management remain challenges for global healthcare systems.
For a long time antispasmodics, laxatives, antidiarrheal and antidepressants together with dietary and lifestyle changes have for many years been the mainstay of treatment for irritable bowel syndrome.
Although pharmacological treatments have proven efficacy in IBS, the illness remains chronic with the symptomatic and functional problems only partially influenced for most patients.
In the United States, the drugs approved for irritable bowel syndrome with diarrhea and constipations in adults includes VIBERZI (eluxadoline), XIFAXAN (rifaximin), LINZESS (linaclotide), IBSRELA (tenapanor), and TRULANCE (plecanatide). Moreover, VIBERZI, LINZESS, IBSRELA, and TRULANCE are running their trials for the pediatric segments.
LINZESS/CONSTELLA (linaclotide) is approved in EU4 and the UK and Japan as well for the treatment of irritable bowel syndrome with constipation, while IRRIBOW (ramosetron) is only approved in Japan.
In 2022, the market size of Irritable Bowel Syndrome was the highest in the US among the 7MM, accounting for approximately USD 1,535 million, which is further expected to increase by 2032.
Among emerging therapies, blautix (4D pharma), Rifamycin SV-MMX (Cosmo Pharmaceuticals), RHB-102 (RedHill Biopharma), Aldafermin (NGM Biopharmaceuticals), and others will be expanding the treatment landscape of irritable bowel syndrome

Irritable Bowel Syndrome Treatment Market
Antispasmodics, laxatives, antidiarrheal and antidepressants together with dietary and lifestyle changes have for many years been the mainstay of treatment for irritable bowel syndrome.
According to the American Gastroenterological Association (2022), first-line drug therapy includes antispasmodics and peppermint oil to treat abdominal pain. Loperamide and laxatives can be tried to treat diarrhea or constipation, respectively. If these approaches fail to improve symptoms, second-line treatments, including secretagogues, rifaximin, low-dose tricyclic antidepressants, and eluxadoline, should be used. If abdominal pain persists, tegaserod and alosetron are recommended.
Over the next few years, the US Irritable Bowel Syndrome Market is expected to substantially change and experience growth, as the current emerging drug, blautix will dominate it. Considering that the complexity and diversity of irritable bowel syndrome presentation makes treatment difficult, which is around 30-40%, we expect the market to expand, especially as safer, satisfactory, and effective disease-modifying therapies enter the market.

Learn more about the treatment market for Irritable Bowel Syndrome @ https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

The Report Covers the Irritable Bowel Syndrome Epidemiology Segmented by:
Irritable Bowel Syndrome Prevalent cases
Irritable Bowel Syndrome Incident Cases
Irritable Bowel Syndrome treatment cases
Irritable Bowel Syndrome Diagnosed cases
Irritable Bowel Syndrome Dug Profile and Companies Covered
4D pharma
Cosmo Pharmaceuticals
RedHill Biopharma Limited
And many others.

Learn more about the Key Companies and Emerging Therapies in the Hemophilia Market @ https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Table of Contents
Key Insights
Irritable Bowel Syndrome Introduction
Executive Summary of Irritable Bowel Syndrome
Disease Background and Overview
Irritable Bowel Syndrome Epidemiology and patient population
Irritable Bowel Syndrome Emerging Therapies
Irritable Bowel Syndrome Market Outlook
Irritable Bowel Syndrome Market Access and Reimbursement of Therapies
Irritable Bowel Syndrome Market Drivers
Irritable Bowel Syndrome Market Barriers
Appendix
Irritable Bowel Syndrome Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Irritable Bowel Syndrome Market Outlook report @
https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Related Reports

Irritable Bowel Syndrome Epidemiology Forecast
https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Irritable Bowel Syndrome Pipeline Forecast
https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.